Common Polymorphism in the LRP5 Gene May Increase the Risk of Bone Fracture and Osteoporosis

Table 2

Meta-analysis of the relationships of LRP5 rs3736228 polymorphism with bone fracture and osteoporosis.

Subgroup analysis	T allele versus C; (allele model)			CT + TT versus CC; (dominant model)			TT versus CC + CT; (recessive model)			TT versus CC; (homozygous model)			TT versus CT; (heterozygous model)
	OR	95% CI		OR	95% CI		OR	95% CI		OR	95% CI		OR	95% CI
Overall	1.19	1.04–1.37	0.014	1.19	0.97–1.46	0.103	1.72	1.16–2.53	0.007	1.76	1.19–2.62	0.005	1.62	1.08–2.44	0.020
Ethnicity
Asian	1.14	0.97–1.33	0.103	1.09	0.88–1.33	0.430	1.75	1.15–2.66	0.009	1.76	1.15–2.70	0.009	1.72	1.11–2.67	0.016
Caucasian	1.42	1.04–1.37	0.027	1.56	1.08–2.25	0.018	1.51	0.53–4.32	0.438	1.77	0.61–5.10	0.290	1.15	0.39–3.38	0.795
Source of controls
PB	1.26	1.01–1.57	0.037	1.29	1.06–1.57	0.010	1.52	0.95–2.43	0.083	1.64	1.02–2.65	0.042	1.32	0.81–2.16	0.263
HB	1.13	0.94–1.37	0.199	0.87	0.62–1.23	0.441	2.24	1.12–4.46	0.022	2.06	1.02–4.17	0.045	2.56	1.23–5.31	0.012
Disease
OP	1.26	1.01–1.57	0.037	1.30	0.95–1.77	0.099	1.47	0.79–2.73	0.219	1.63	0.87–3.05	0.124	1.24	0.65–2.35	0.508
Fracture	1.13	0.94–1.37	0.199	1.06	0.84–1.34	0.619	1.90	1.15–3.14	0.012	1.86	1.11–3.10	0.018	1.95	1.15–3.29	0.013
Genotyping method
Non-TaqMan assay	1.16	0.74–1.83	0.513	1.21	0.64–2.30	0.557	1.13	0.40–3.19	0.813	1.20	0.42–3.39	0.735	1.00	0.34–2.92	0.997
TaqMan assay	1.20	1.03–1.40	0.021	1.17	0.97–1.41	0.108	1.84	1.21–2.80	0.005	1.88	1.23–2.89	0.004	1.76	1.13–2.73	0.012

OR: odds ratio and 95% CI: 95% confidence interval.